Methods and Compositions Comprising Polycationic Compounds

Abstract

The invention relates to the use of a polycationic compound for the preparation of a medicament with retarded in vivo release.

1 - 13 . (canceled)  
     
     
         14 . A method of vaccinating comprising administering to a subject at a subcutaneous, intradermal, transdermal, or intramuscular site of administration a polycationic peptide and an antigen, wherein a depot effect is induced at the site of administration.  
     
     
         15 . A method of vaccinating comprising administering to a subject at a subcutaneous, intradermal, transdermal, or intramuscular site of administration a polycationic peptide, an antigen, and an immunostimulatory nucleic acid molecule, wherein a depot effect is induced at the site of administration.  
     
     
         16 . A method of vaccinating comprising injecting into a subject at a subcutaneous, intradermal, transdermal, or intramuscular site of administration a polycationic peptide, an antigen, and an immunostimulatory nucleic acid molecule, wherein a depot effect is induced at the site of administration.  
     
     
         17 . The method of  claim 15  or  16 , wherein the immunostimulatory nucleic acid molecule is a CpG-ODN or ODN (I-ODN).  
     
     
         18 . The method of any one of  claim 14  to  16 , wherein the polycationic peptide is a basic polypeptide.  
     
     
         19 . The method of any one of  claim 14  to  16 , wherein the polycationic peptide is a polylysine or a polypeptide containing more than 50% of basic amino acid residues.  
     
     
         20 . The method of  claim 19 , wherein the polypeptide containing more than 50% of basic amino acid residues is between 5 to 500 amino acid residues.  
     
     
         21 . The method of  claim 19 , wherein the polypeptide containing more than 50% of basic amino acid residues is between 10 to 200 amino acid residues.  
     
     
         22 . The method of any one of  claim 14  to  16 , wherein the polycationic peptide comprises a synthetic peptide containing at least two KLK-motifs separated by a linker of 3 to 7 hydrophobic amino acids.  
     
     
         23 . The method of any one of  claim 14  to  16 , wherein the polycationic peptide comprises a polycationic anti-microbial peptide.  
     
     
         24 . The method of  claim 23 , wherein the polycationic anti-microbial peptide is produced chemically.  
     
     
         25 . The method of  claim 23 , wherein the polycationic anti-microbial peptide is produced recombinantly.  
     
     
         26 . The method of any one of  claim 14  to  16 , wherein the depot effect is present at the site of administration or injection 4 days after administration.  
     
     
         27 . The method of any one of  claim 14  to  16 , wherein the depot effect is present at the site of administration or injection 14 days after administration.  
     
     
         28 . The method of any one of  claim 14  to  16 , wherein the depot effect is present at the site of administration or injection 19 days after administration.  
     
     
         29 . The method of any one of  claim 14  to  16 , wherein the antigen is a T cell epitope of 8 to 11 amino acids in length.  
     
     
         30 . The method of any one of  claim 14  to  16 , wherein the antigen is from a viral pathogen, a bacterial pathogen, a eukaryotic pathogen, a tumor antigen, or an autoimmune antigen.